BRAF and neoplasm: More specifically, findings of a heterogeneously distributed BRAF mutation that is confined to a subset of tumor cells in small-size tumors (de Biase et al., 2014; Finkel et al., 2016) suggest that monoclonality for BRAF predominating in more-advanced stages of PTC is the result of tumor evolution.